Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:FATE NASDAQ:NBIX NASDAQ:VIR NASDAQ:XLRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$62.94+6.6%$57.05$30.04▼$71.13$5.37B1.811.83 million shs2.78 million shsFATEFate Therapeutics$1.00+5.3%$1.08$0.66▼$4.20$109.56M2.211.28 million shs1.34 million shsNBIXNeurocrine Biosciences$145.66+2.1%$135.03$84.23▼$154.61$14.16B0.28710,775 shs788,875 shsVIRVir Biotechnology$5.18+7.9%$5.02$4.16▼$14.45$666.80M1.281.48 million shs1.27 million shsXLRNAcceleron Pharma$178.75$176.25$108.82▼$189.99$10.93B0.13572,759 shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+6.55%+12.61%+16.21%+42.24%+26.92%FATEFate Therapeutics+5.26%-1.96%-12.28%-15.97%-74.23%NBIXNeurocrine Biosciences+2.05%+1.43%+9.68%+15.10%+21.54%VIRVir Biotechnology+7.92%-0.96%+18.81%-0.96%-33.59%XLRNAcceleron Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$62.94+6.6%$57.05$30.04▼$71.13$5.37B1.811.83 million shs2.78 million shsFATEFate Therapeutics$1.00+5.3%$1.08$0.66▼$4.20$109.56M2.211.28 million shs1.34 million shsNBIXNeurocrine Biosciences$145.66+2.1%$135.03$84.23▼$154.61$14.16B0.28710,775 shs788,875 shsVIRVir Biotechnology$5.18+7.9%$5.02$4.16▼$14.45$666.80M1.281.48 million shs1.27 million shsXLRNAcceleron Pharma$178.75$176.25$108.82▼$189.99$10.93B0.13572,759 shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+6.55%+12.61%+16.21%+42.24%+26.92%FATEFate Therapeutics+5.26%-1.96%-12.28%-15.97%-74.23%NBIXNeurocrine Biosciences+2.05%+1.43%+9.68%+15.10%+21.54%VIRVir Biotechnology+7.92%-0.96%+18.81%-0.96%-33.59%XLRNAcceleron Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.50Moderate Buy$71.5013.60% UpsideFATEFate Therapeutics 2.14Hold$3.30230.00% UpsideNBIXNeurocrine Biosciences 2.85Moderate Buy$160.2610.03% UpsideVIRVir Biotechnology 2.90Moderate Buy$17.30233.98% UpsideXLRNAcceleron Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CRSP, NBIX, XLRN, VIR, and FATE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025CRSPCRISPR TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$70.009/15/2025VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.009/5/2025NBIXNeurocrine BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$144.00 ➝ $149.009/5/2025NBIXNeurocrine BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$158.00 ➝ $163.009/3/2025VIRVir BiotechnologyEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$12.008/27/2025VIRVir BiotechnologyBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$12.00 ➝ $14.008/26/2025CRSPCRISPR TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $2.508/7/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $80.008/6/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$42.00 ➝ $56.008/5/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$82.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M163.55N/AN/A$22.64 per share2.78FATEFate Therapeutics$13.63M8.46N/AN/A$2.80 per share0.36NBIXNeurocrine Biosciences$2.36B6.13$3.45 per share42.23$25.58 per share5.69VIRVir Biotechnology$74.21M9.70N/AN/A$8.35 per share0.62XLRNAcceleron Pharma$92.52M118.15N/AN/A$11.74 per share15.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.45N/AN/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)NBIXNeurocrine Biosciences$341.30M$3.3843.0922.511.0313.88%13.22%9.39%10/29/2025 (Estimated)VIRVir Biotechnology-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%10/30/2025 (Estimated)XLRNAcceleron Pharma-$166.03M-$4.21N/AN/AN/A-226.01%-32.11%-29.45%N/ALatest CRSP, NBIX, XLRN, VIR, and FATE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 million8/6/2025Q2 2025VIRVir Biotechnology-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 million7/30/2025Q2 2025NBIXNeurocrine Biosciences$0.98$1.06+$0.08$1.06$653.09 million$687.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AXLRNAcceleron PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A16.6116.61FATEFate TherapeuticsN/A8.048.04NBIXNeurocrine BiosciencesN/A3.203.10VIRVir BiotechnologyN/A7.017.01XLRNAcceleron PharmaN/A12.1412.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%FATEFate Therapeutics97.54%NBIXNeurocrine Biosciences92.59%VIRVir Biotechnology65.32%XLRNAcceleron Pharma90.35%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%FATEFate Therapeutics5.51%NBIXNeurocrine Biosciences4.80%VIRVir Biotechnology16.00%XLRNAcceleron Pharma1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46090.95 million87.04 millionOptionableFATEFate Therapeutics550115.33 million108.98 millionOptionableNBIXNeurocrine Biosciences1,80099.18 million94.42 millionOptionableVIRVir Biotechnology580138.92 million116.69 millionOptionableXLRNAcceleron Pharma31261.16 million60.12 millionOptionableCRSP, NBIX, XLRN, VIR, and FATE HeadlinesRecent News About These CompaniesAcceleron P Stock Price Today | NASDAQ: XLRN Live - Investing.comJune 28, 2025 | investing.comUK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma DealJanuary 2, 2025 | benzinga.comAcceleron advances cold fusion technologyDecember 17, 2024 | neimagazine.comNAcceleron Banks on Muons for Colder FusionDecember 6, 2024 | msn.comMerck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH studyNovember 26, 2024 | fiercepharma.comFAcceleron attracts turbocharged demand for debut SwissieOctober 17, 2024 | globalcapital.comGAcceleron Fusion has raised $15M to take a stab at colder fusion, filing revealsOctober 5, 2024 | techcrunch.comTAcceleron Fusion has raised $15M to take another stab at cold fusion, filing revealsOctober 1, 2024 | yahoo.comMerck confirms $11.5bn Acceleron takeover dealAugust 6, 2024 | pharmaphorum.comPEarnings to Watch Next Week: ON Semiconductor, Ferrari, General Motors and Moderna in FocusApril 26, 2024 | fxempire.comFBig Pharma Q1 earnings roundup: AstraZeneca, BMS, Merck, SanofiApril 26, 2024 | mmm-online.comMORBIMED CAPITAL GP II LLC's Net WorthFebruary 27, 2024 | benzinga.comXLRN Historical DataOctober 20, 2023 | investing.comMSD eyes March FDA decision on PAH drug sotaterceptOctober 15, 2023 | pharmaphorum.comPBrexit Bargain Buys: 14 More Stocks Picked by Morgan StanleyApril 15, 2023 | thestreet.comAstellas Pharma IncMarch 17, 2023 | reuters.comHempStreet partners with MGC Pharma launches ArtemiCJanuary 30, 2023 | health.economictimes.indiatimes.comAcceleron Corp Becomes a Digital Correspondent BankDecember 14, 2022 | finance.yahoo.comPharma Contract Sales Market Report 2022-2032November 30, 2022 | finance.yahoo.comMerck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugsNovember 21, 2022 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025New Age Warfare: Anduril Is the Hype, AeroVironment Is the BuyBy Jeffrey Neal Johnson | August 28, 2025Take the Money and Run: Strategy Stock Looks Tapped OutBy Gabriel Osorio-Mazilli | September 9, 2025AeroVironment Is a Hot Buy With a Double-Digit UpsideBy Thomas Hughes | September 11, 2025CRSP, NBIX, XLRN, VIR, and FATE Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$62.94 +3.87 (+6.55%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$63.40 +0.46 (+0.72%) As of 06:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Fate Therapeutics NASDAQ:FATE$1.00 +0.05 (+5.26%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$1.01 +0.01 (+0.60%) As of 06:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Neurocrine Biosciences NASDAQ:NBIX$145.66 +2.93 (+2.05%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$144.82 -0.84 (-0.58%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Vir Biotechnology NASDAQ:VIR$5.18 +0.38 (+7.92%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$5.14 -0.04 (-0.75%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Acceleron Pharma NASDAQ:XLRNAcceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
